2
Results-
Press ReleaseRARE DISEASE DAY – February 28th, 2023Created on : - Last modified on :Pierre Fabre pursues its commitment against rare diseases in the pediatric, oncology and dermatology fields. The diseases are rare, but they impact a lot of people : nearly 300 million people are affected worldwide1.
-
Press ReleasePierre Fabre and the EspeRare Foundation start the EDELIFE clinical trial of a prenatal treatment for a rare genetic disease, XLHEDCreated on : - Last modified on :Geneva, Switzerland, Castres, France (November 15, 2021) – The EspeRare Foundation and the Pierre Fabre group announced today the start of the EDELIFE clinical trial aimed at confirming the safety and efficacy of ER004, a prenatal treatment for XLHED (X-linked Hypohidrotic Ectodermal Dysplasia), a rare and debilitating congenital disease. If positive, the study could lead to the first approved treatment for XLHED by 2026.
We take care of life by designing and developing innovative solutions inspired by consumers and patients, and contributing to the well-being of everyone from health to beauty.